Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.

Phuoc T Tran,Kathryn Lowe,Hua-Ling Tsai,Daniel Y Song,Arthur Y Hung,Jason W D Hearn,Steven Miller,James A Proudfoot,Matthew P Deek,Ryan Phillips,Tamara Lotan,Channing J Paller,Catherine H Marshall,Mark Markowski,Shirl Dipasquale,Samuel Denmeade,Michael Carducci,Mario Eisenberger,Theodore L DeWeese,Matthew Orton,Curtiland Deville,Elai Davicioni,Stanley L Liauw,Elisabeth I Heath,Stephen Greco,Neil B Desai,Daniel E Spratt,Felix Feng,Hao Wang,Tomasz M Beer,Emmanuel S Antonarakis

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2022）

Cited 4|Views30
No score
Abstract
SRT plus ENZA monotherapy for 6 months in men with PSA-recurrent high-risk prostate cancer after RP is safe and delays PSA progression relative to SRT alone. The impact of ENZA on distant metastasis or survival is unknown at this time.
More
Translated text
Key words
radical prostatectomy,salvage radiation therapy,enzalutamide,high-risk,prostate-specific,salv-enza
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined